169 related articles for article (PubMed ID: 31832974)
1. Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany.
Müller S; Heidler T; Fuchs A; Pfaff A; Ernst K; Ladinek G; Wilke T
Neurol Ther; 2020 Jun; 9(1):67-83. PubMed ID: 31832974
[TBL] [Abstract][Full Text] [Related]
2. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
3. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
[TBL] [Abstract][Full Text] [Related]
4. Impact of multiple sclerosis phenotypes on burden of disease in Finland.
Purmonen T; Hakkarainen T; Tervomaa M; Ruutiainen J
J Med Econ; 2020 Feb; 23(2):156-165. PubMed ID: 31617776
[No Abstract] [Full Text] [Related]
5. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study.
Blinkenberg M; Kjellberg J; Ibsen R; Magyari M
Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969
[TBL] [Abstract][Full Text] [Related]
6. The Rao's Brief Repeatable Battery in the study of cognition in different multiple sclerosis phenotypes: application of normative data in a Serbian population.
Dackovic J; Pekmezovic T; Mesaros S; Dujmovic I; Stojsavljevic N; Martinovic V; Drulovic J
Neurol Sci; 2016 Sep; 37(9):1475-81. PubMed ID: 27207679
[TBL] [Abstract][Full Text] [Related]
7. The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis.
Perrone V; Veronesi C; Giacomini E; Citraro R; Dell'Orco S; Lena F; Paciello A; Resta AM; Nica M; Ritrovato D; Degli Esposti L
Clin Epidemiol; 2022; 14():1327-1337. PubMed ID: 36387930
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of antioxidant parameters of multiple sclerosis patients' serum according to the disease course.
Nowak-Kiczmer M; Niedziela N; Zalejska-Fiolka J; Adamczyk-Sowa M
Mult Scler Relat Disord; 2023 Sep; 77():104875. PubMed ID: 37454567
[TBL] [Abstract][Full Text] [Related]
9. Disease-modifying Therapies for Multiple Sclerosis.
Corboy JR; Goodin DS; Frohman EM
Curr Treat Options Neurol; 2003 Jan; 5(1):35-54. PubMed ID: 12521562
[TBL] [Abstract][Full Text] [Related]
10. Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities.
Chataway J; Murphy N; Khurana V; Schofield H; Findlay J; Adlard N
Curr Med Res Opin; 2021 Jun; 37(6):995-1004. PubMed ID: 33733976
[No Abstract] [Full Text] [Related]
11. Profile of Polish patients with primary progressive multiple sclerosis.
Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A
Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082
[TBL] [Abstract][Full Text] [Related]
12. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Rovira À; Montalban X; Kearney H; Ciccarelli O; Matthews L; Palace J; Gallo A; Bisecco A; Gass A; Eisele P; Lukas C; Bellenberg B; Barkhof F; Vrenken H; Preziosa P; Comi G; Filippi M;
Neurology; 2019 Nov; 93(20):e1852-e1866. PubMed ID: 31611336
[TBL] [Abstract][Full Text] [Related]
13. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
14. Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in Sweden.
Gyllensten H; Kavaliunas A; Murley C; Alexanderson K; Hillert J; Tinghög P; Friberg E
Mult Scler J Exp Transl Clin; 2019; 5(2):2055217319858383. PubMed ID: 31285832
[TBL] [Abstract][Full Text] [Related]
15. Income in Multiple Sclerosis Patients with Different Disease Phenotypes.
Kavaliunas A; Manouchehrinia A; Danylaite Karrenbauer V; Gyllensten H; Glaser A; Alexanderson K; Hillert J
PLoS One; 2017; 12(1):e0169460. PubMed ID: 28081163
[TBL] [Abstract][Full Text] [Related]
16. Late onset multiple sclerosis: Is it really late onset?
Roohani P; Emiru T; Carpenter A; Luzzio C; Freeman J; Scarberry S; Beaver G; Davidson L; Parry G
Mult Scler Relat Disord; 2014 Jul; 3(4):444-9. PubMed ID: 25877055
[TBL] [Abstract][Full Text] [Related]
17. Regional white matter atrophy--based classification of multiple sclerosis in cross-sectional and longitudinal data.
Sampat MP; Berger AM; Healy BC; Hildenbrand P; Vass J; Meier DS; Chitnis T; Weiner HL; Bakshi R; Guttmann CR
AJNR Am J Neuroradiol; 2009 Oct; 30(9):1731-9. PubMed ID: 19696139
[TBL] [Abstract][Full Text] [Related]
18. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
Ratzer R; Søndergaard HB; Christensen JR; Börnsen L; Borup R; Sørensen PS; Sellebjerg F
Mult Scler; 2013 Dec; 19(14):1841-8. PubMed ID: 24085340
[TBL] [Abstract][Full Text] [Related]
19. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ
CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001
[TBL] [Abstract][Full Text] [Related]
20. Clinical course of multiple sclerosis and labour-force absenteeism: a longitudinal population-based study.
Castelo-Branco A; Landfeldt E; Svedbom A; Löfroth E; Kavaliunas A; Hillert J
Eur J Neurol; 2019 Apr; 26(4):603-609. PubMed ID: 30414299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
